GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Degree of Financial Leverage

ACTU (Actuate Therapeutics) Degree of Financial Leverage : 0.38 (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Actuate Therapeutics's Degree of Financial Leverage for the quarter that ended in Mar. 2025 was 0.38. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Actuate Therapeutics's Degree of Financial Leverage or its related term are showing as below:

ACTU's Degree of Financial Leverage is ranked better than
74.1% of 1448 companies
in the Biotechnology industry
Industry Median: 0.95 vs ACTU: 0.38

Actuate Therapeutics Degree of Financial Leverage Historical Data

The historical data trend for Actuate Therapeutics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Degree of Financial Leverage Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Degree of Financial Leverage
- -0.15 0.99

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.85 0.99 0.38

Competitive Comparison of Actuate Therapeutics's Degree of Financial Leverage

For the Biotechnology subindustry, Actuate Therapeutics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actuate Therapeutics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Degree of Financial Leverage falls into.


;
;

Actuate Therapeutics Degree of Financial Leverage Calculation

Actuate Therapeutics's Degree of Financial Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -1.544 (Mar. 2025) / -1.598 (Mar. 2024) - 1 )/( -25.287 (Mar. 2025) / -27.75 (Mar. 2024) - 1 )
=-0.0338/-0.0888
=0.38***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Actuate Therapeutics  (NAS:ACTU) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Actuate Therapeutics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Actuate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.